Moderna Takes Its First Autoimmune Therapeutic Candidate To Human Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first patient in the Phase 1 study of mRNA-6231, its mRNA-encoded IL-2 modified to expand regulatory T cells.
mRNA-6231 is Moderna's first autoimmune candidate to enter the clinic. It is also Moderna's first subcutaneously administered therapeutic program.
The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA‑6231 in healthy adult participants.
mRNA‑6231 is a lipid nanoparticle encapsulated mRNA-based therapeutic that encodes for mutein human interleukin 2, fused to human serum albumin (HSA‑IL2m) to achieve enhanced selectivity toward T regulatory cells.
IL-2 through preferential expansion of Tregs is hypothesized to play a central role in restoring immune homeostasis.
Price Action: MRNA shares are down 0.51% at $351.80 during the market session on the last check Monday.